Brief: Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich Lifesciences

14/02/2024 11:08

Feb 14 (Reuters) - Greenwich Lifesciences Inc  GLSI.O :
    * GREENWICH LIFESCIENCES PROVIDES UPDATE ON PHASE III
CLINICAL
TRIAL, FLAMINGO-01
    * GREENWICH LIFESCIENCES INC - FLAMINGO-01 DSMB MET TWICE IN
2023
AND RECOMMENDED TO CONTINUE STUDY AS IS WITHOUT MODIFICATION
    * GREENWICH LIFESCIENCES INC - NO SERIOUS ADVERSE EVENTS
RELATED
TO GLSI-100 HAVE BEEN REPORTED TO DATE
    * GREENWICH LIFESCIENCES INC -  ANTICIPATES ADDING UP TO AN
ADDITIONAL 10 SITES PARTICIPATING IN FLAMINGO-01 IN 2024
    * GREENWICH LIFESCIENCES INC - WILL AMEND FLAMINGO-01
PROTOCOL TO
ALLOW UP TO 250 PATIENTS TO ENROLL IN OPEN-LABEL ARM OF STUDY

Source text for Eikon:  ID:nGNX3mwrPY 
Further company coverage:  GLSI.O 

 ((Reuters.Briefs@thomsonreuters.com;))